The gamma-glutamyl transferase to platelet ratio and the FIB-4 score are noninvasive markers to determine the severity of liver fibrosis in chronic hepatitis B infection

Lee, Jiyoul; My, Kim; Kang, SH; Kim, J; Uh, Young; Yoon, K.T.; Hs, Kim

doi:10.1080/09674845.2018.1459147

Cited by 24 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with these findings, Lee et al [56] also showed that GPR and FIB-4 can significantly screen the liver fibrosis status in CHB patients and that GPR displayed the best diagnostic performance.…”

Section: Crp To Albumin Ratio (Car)supporting

confidence: 58%

Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases

Mao

2020

Disease Markers

View full text Add to dashboard Cite

A series of predictive scoring systems is available for stratifying the severity of conditions and assessing the prognosis in patients with HBV-related liver diseases. We show nine of the most popular serum biomarkers and their models (i.e., serum cystatin C, homocysteine, C-reactive protein, C-reactive protein to albumin ratio, aspartate aminotransferase to platelet ratio index, fibrosis index based on four factors, gamma-glutamyl transpeptidase to platelet ratio, albumin-bilirubin score, and gamma-glutamyl transpeptidase to albumin ratio) that have gained great interest from clinicians. Compared with traditional scoring systems, these serum biomarkers and their models are easily acquired, simple, and relatively inexpensive. In the present review, we summarize the latest studies focused on these serum biomarkers and their models as diagnostic and prognostic indexes in HBV-related liver diseases.

show abstract

Section: Crp To Albumin Ratio (Car)supporting

confidence: 58%

Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases

Mao

2020

Disease Markers

View full text Add to dashboard Cite

show abstract

“…On the other hand, it should be noted that the findings presented in this study indicate the inability of predicting the severity of hepatic fibrosis among PSC patients based on the platelet-dependent models such as aspartate aminotransferase-to-platelet ratio index, gamma-glutamyl transferase-to-platelet ratio, fibrosis index based on the 4 factors, and red blood cell distribution width-to-platelet ratio. [51][52][53][54][55] Therefore, in the PSC-C patients, this context of platelet count status should be considered in the application of models predicting progression to cirrhosis. Recently, in a large cohort of PSC patients from the United Kingdom (UK-PSC score), a new risk scoring model was developed in order to predict the outcome of patients diagnosed with PSC.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Platelet Count Reduction in Patients awaiting Liver Transplantation with and without Primary Sclerosing Cholangitis: A Cohort Study

et al. 2020

View full text Add to dashboard Cite

Background:Thrombocytopenia is the most well-known hematological abnormality occurring in patients with liver cirrhosis. However, the rate of platelet count reduction is not the same across different chronic liver disease etiologies. Therefore, the aim of the present study was to compare the differences in the platelet count levels between primary sclerosing cholangitis-related cirrhosis (PSC-C) and other causes of liver disease. Methods:In this cohort study, the association between PSC-C and risk of platelet count reduction was investigated. The platelet counts were repeatedly measured among 242 consecutive cirrhotic patients (144 males and 98 females) including 67 patients with PSC-C and 175 patients with non-PSC-C who were on the waiting list for liver transplantation. The Poisson regression analysis was used to assess the relationship between platelet count reduction and PSC-C, after adjusting for potential confounding factors. Results: During the five years of follow-up, comparison between the two groups revealed that significantly higher levels of platelet were found in PSC-C patients when compared to the non-PSC-C group [148 (106–280) (×103 /µL) vs. 79 (50–110) (×103 /µL), respectively, P < 0.001]. After adjusting for confounding factors, a significant association was observed between non-PSC-C and the risk of platelet count reduction (relative risk, RR: 14.81, 95% CI: 1.21–160.42; P= 0.03). Conclusion: The findings indicate that PSC-C patients present with mild degrees of thrombocytopenia compared to other causes of chronic liver disease.

show abstract

“…In recent years, the combined analysis of liver enzymes and platelet counts has provided important information regarding the role of new biomarkers in predicting neoplastic and infectious disease severity [47, 48]. One of these biomarkers, the APRI, has been widely studied as a minimally invasive marker of fibrosis and inflammation in hepatic disease [49, 50].…”

Section: Discussionmentioning

confidence: 99%

Aspartate aminotransferase-to-platelet ratio index (APRI): A potential marker for diagnosis in patients at risk of severe malaria caused by Plasmodium vivax

et al. 2019

View full text Add to dashboard Cite

Acute infection with Plasmodium vivax, classically associated with benign disease, has been presenting as serious and even fatal disease in recent years. Severe disease is mainly due to biochemical and hematological alterations during the acute phase of infection. In the present cross-sectional study, the aspartate aminotransferase-to-platelet ratio index (APRI) was evaluated as a method for identifying patients at risk of severe vivax malaria. This retrospective study included 130 patients with confirmed P. vivax infection between June 2006 and January 2018. Clinical-epidemiological data were obtained from medical records. Hematological and biochemical parameters were determined using automated equipment. The criteria of severity for infection by Plasmodium falciparum, established by the World Health Organization (WHO), were adapted to classify patients with danger signs of severe vivax malaria. Of the 130 patient’s records evaluated, 19 (14.6%) had one or more signs and symptoms of severe malaria. The mean APRI values among patients with and without severe malaria were 2.11 and 1.09, respectively (p = 0.044). Among those with severe disease, the proportion with an APRI value above 1.50 was 30% compared to the 10% among those without severe disease (p = 0.007). The area under the receiver operating characteristic curve (95% CI), calculated to assess the accuracy of the APRI in discriminating between patients with and without severe disease, was 0.645 (0.494; 0.795). An APRI cutoff of 0.74 resulted in sensitivity of 74.0%, specificity of 56.0%, and accuracy of 65.0%. This study shows that the APRI is elevated in patients with evidence of infection by P. vivax. Based on the good sensitivity found in this study, we conclude that this simple index can serve as a diagnostic biomarker to identify patients at risk of severe disease during the acute phase of P. vivax infection.

show abstract

The gamma-glutamyl transferase to platelet ratio and the FIB-4 score are noninvasive markers to determine the severity of liver fibrosis in chronic hepatitis B infection

Cited by 24 publications

References 26 publications

Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases

Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases

Comparison of Platelet Count Reduction in Patients awaiting Liver Transplantation with and without Primary Sclerosing Cholangitis: A Cohort Study

Aspartate aminotransferase-to-platelet ratio index (APRI): A potential marker for diagnosis in patients at risk of severe malaria caused by Plasmodium vivax

Contact Info

Product

Resources

About